0.00Open6.32Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV-3.30%PremiumDec 6, 2024Expiry Date6.57Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.20Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet